Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

372P - Sympathetic signals promote immunosuppressive neutrophils for tumor progression in the lung

Date

28 Mar 2025

Session

Poster Display session

Presenters

Ruoyi Jin

Citation

Journal of Thoracic Oncology (2025) 20 (3): S208-S232. 10.1016/S1556-0864(25)00632-X

Authors

R. Jin1, J. Liu2, H. Chen3, W. Wang4, Y. Jin4, M. Qiu1, Y. Cao5, J. Chen6, K. Chen1, J. Yang2

Author affiliations

  • 1 Peking University People's Hospital, Beijing/CN
  • 2 State Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing/CN
  • 3 Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program, Peking University, Beijing/CN
  • 4 Department of Thoracic Surgery, Peking University People's Hospital, Beijing/CN
  • 5 Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing/CN
  • 6 Chinese Institute for Brain Research, Beijing, Beijing/CN

Resources

This content is available to ESMO members and event participants.

Abstract 372P

Background

The nervous system’s role in tumor progression has been recognized, but mechanisms of neural modulation in lung tumor microenvironment are elusive.

Methods

Immunotherapy effectiveness in 98 EGFR-negative Non-small Cell Lung Cancer (NSCLC) patients using β-blockers was analyzed. Tumor sympathetic innervation was mapped using whole-tissue immunolabeling and 3D imaging in 20 NSCLC, 7 metastatic lung tumors (breast/colorectal origin), and 5 benign samples, alongside C57BL/6 orthotopic Lewis lung carcinoma and MMTV-PyMT +/− mouse models. Sympathetic ablation was achieved via intranasal 6-Hydroxydopamine and sympathectomy. Single-cell RNA sequencing (scRNA-seq) identified immunosuppressive neutrophil subtypes, and neutrophil-specific β2-adrenergic receptor (Adrb2) signal was blocked using Ly6g-Cre;Adrb2fl/fl mice and pharmacological inhibition.

Results

Firstly, we noted β-blocker administration significantly improved immunotherapy outcomes in NSCLC patients, evidenced by higher complete or partial response rates, highlighting the therapeutic benefits of sympathetic signal inhibition. Then, using 3D imaging techniques, abundant sympathetic innervations were detected within primary and metastatic lung tumors and proved to project inside them in both human and mouse models, but were absent in benign samples. Ablation of local sympathetic inputs in mice, either chemically or surgically, suppressed lung tumor progression and increased CD8+ T cell infiltration, demonstrating sympathetic pathways regulating tumor growth and immunity. To explore molecular mechanism, scRNA-seq revealed immunosuppressive neutrophils with elevated Cd274 expression andmyeloid recruitment factors, uniquely enriched in both primary and metastatic lung tumors. Sympathetic Adrb2 signaling enhanced the immunosuppressive gene expression and tumor-promoting activity of these neutrophils. Targeted inhibition of Adrb2 reduced CD274+ neutrophils, diminished tumor progression, and prolonged survival in primary and metastatic mouse models, confirming their role.

Conclusions

This study first revealed that sympathetic nerves promote lung tumor progression through immunosuppressive neutrophils in the microenvironment.

Legal entity responsible for the study

J. Yang

Funding

This work has been supported by the National Key Research and Development Program of China (#2023YFA1801901 to J.Y.; #2022YFA1103900 to J.C.), the National Natural Science Foundation of China (#32125017 and #32150008 to J.Y.; #82388102 and #92259303 to K.C.; #82173386 to M.Q.), the Beijing Natural Science Foundation (#Z240013 and #L234002 to K.C.; #7232086 to J.Y; #7234378 to Y.C; #QY23070 to R.J.), the Chinese Academy of Medical Sciences (#2021RU002 and #2022-I2M-C&T-B-120 to K.C.; #2019-I2M-5-015 to J.C.), and Peking University People’s Hospital Scientific Research Development Funds (#RZG2024-02 to K.C.; #RZ2022-04 to M.Q.).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.